A case–control studyEvaluating the role of leukotriene receptor antagonists in preventing the cardiovascular and cerebrovascular disease

  1. Hoxha, M. 1
  2. V. Malaj 2
  3. M. Vara-Messler 3
  4. C.R. Doce 4
  5. A.B. Cavanillas 4
  1. 1 University of Milan
    info

    University of Milan

    Milán, Italia

    ROR https://ror.org/00wjc7c48

  2. 2 University of Tirana
    info

    University of Tirana

    Tirana, Albania

    ROR https://ror.org/03g9v2404

  3. 3 University of Turin
    info

    University of Turin

    Turín, Italia

    ROR https://ror.org/048tbm396

  4. 4 Universidad de Granada
    info

    Universidad de Granada

    Granada, España

    ROR https://ror.org/04njjy449

Mostrar afiliaciones +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Año de publicación: 2021

Número: 1

Páginas: 4-11

Tipo: Artículo

DOI: 10.1016/J.SEMERG.2020.09.008 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Semergen: revista española de medicina de familia

Resumen

Introducción Los antagonistas del receptor de leucotrienos (LTRAs) se utilizan como alternativa terapéutica en pacientes asmáticos. Diferentes estudios en animales sugieren que los LTRAs pueden disminuir la hiperplasia de la íntima después de una lesión vascular, ejerciendo así un papel protector sobre la isquemia vascular. Objetivo El objetivo de este estudio fue evaluar el papel del antagonista del receptor de leucotrienos en la prevención de la cardiopatía isquémica y los accidentes cerebrovasculares en humanos. Material y método Se realizó un estudio de casos y controles retrospectivos para investigar el efecto de la LTRAs sobre el riesgo de infarto agudo de miocardio (IAM) y accidente cerebrovascular isquémico (ACV). Los casos fueron pacientes ingresados en el Hospital Universitario San Cecilio de Granada; para cada caso se tomaron dos grupos de controles apareados por sexo y edad, entre pacientes adscritos a dos Centros de Atención Primaria de Salud de Granada con diagnóstico de asma. Resultados Se incluyeron 59 casos de IAM y 108 casos de ACV, e igual número de controles apareados por sexo y edad de cada uno de los dos Centros de Salud. El tratamiento con LTRAs se asoció con un aumento no significativo del riesgo de IAM (OR = 1,74; IC 95% 0,61- 4,96), y al contrario, con una ligera reducción del riesgo de accidente cerebrovascular, tanto cuando se estudió cada uno de los grupos de controles de forma independiente (OR = 0,74; IC 95% 0,37-1,47 para el primer centro; OR = 0,82; IC 95% 0,4 -1,67 para el segundo centro), como cuando se combinaron los dos grupos de controles (OR 0,63; IC 95% 0,32 -1,26). En ningún caso se alcanzó una significación estadística. Conclusiones Los resultados no permiten confirmar el efecto protector sobre el riesgo cardiovascular sugerido por estudios previos realizados en animales.

Referencias bibliográficas

  • V. Capra, M.D. Thompson, A. Sala, D.E. Cole, G. Folco, G.E. Rovati Cysteinyl leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends Med Res Rev, 27 (2007), pp. 469-527, 10.1002/med.20071 CrossRefView Record in ScopusGoogle Scholar
  • C. Brink, S.E. Dahlén, J. Drazen, J.F. Evans, D.W. Hay, S. Nicosia, et al. International union of pharmacology XXXVII: nomenclature for leukotriene and lipoxin receptors Pharmacol Rev, 55 (2003), pp. 195-227, 10.1124/pr.55.1.8 View Record in ScopusGoogle Scholar
  • D. Poeckel, C.D. Funk The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease Cardiovasc Res, 86 (2010), pp. 243-253, 10.1093/cvr/cvq016 CrossRefView Record in ScopusGoogle Scholar
  • J. Chu, D. Praticò The 5-lipoxygenase as a common pathway for pathological brain and vascular aging Cardiovasc Psychiatry Neurol, 2009 (2009), pp. 174-657, 10.1155/2009/174657 CrossRefGoogle Scholar
  • E. Ingelsson, L. Yin, M. Bäck Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease J Allergy Clin Immunol, 129 (2012), pp. 702-707, 10.1016/j.jaci.2011.11.052 View Record in ScopusGoogle Scholar
  • H.D. Yun, E. Knoebel, Y. Fenta, S.E. Gabriel, C.L. Leibson, E.V. Loftus, et al. Asthma and proinflammatory conditions: a population-based retrospective matched cohort study Mayo Clin Proc, 87.10 (2016), pp. 953-960, 10.1016/j.mayocp.2012.05.020 Google Scholar
  • M. Hoxha, G.E. Rovati, A.B. Cavanillas The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field Eur J Clin Pharmacol, 73 (2017), pp. 799-809, 10.1007/s00228-017-2242-2 CrossRefView Record in ScopusGoogle Scholar
  • Y. Toki, N. Hieda, T. Torii, H. Hashimoto, T. Ito, K. Ogawa, et al. The effects of lipoxygenase inhibitor and peptidoleukotriene antagonist on myocardial injury in a canine coronary occlusion-reperfusion model Prostaglandins, 35 (1988), pp. 555-571, 10.1016/0090-6980(88)90031-7 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C.E. Hock, L.D. Beck, L.A. Papa Peptide leukotriene receptor antagonism in myocardial ischemia and reperfusion Cardiovasc Resp, 26 (1992), pp. 1206-1211, 10.1093/cvr/26.12.1206 CrossRefView Record in ScopusGoogle Scholar
  • T. Ito, Y. Toki, N. Hieda, K. Okumura, H. Hashimoto, K. Ogawa, et al. Protective effects of a thromboxane synthetase inhibitor a thromboxane antagonist a lypoxigenase inhibitor a leukotriene C4 D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart Jpn Circ J, 53 (1989), pp. 1115-1121, 10.1253/jcj.53.1115 CrossRefView Record in ScopusGoogle Scholar
  • R.A. Hahn, B.R. MacDonald, E. Morgan, B.D. Potts, C.J. Parli, L.E. Rinkema, et al. Evaluation of LY203647 on cardiovascular leukotriene D4 receptors and myocardial reperfusion injury J Pharmacol Exp Ther, 260 (1992), pp. 979-989 1312172 View Record in ScopusGoogle Scholar
  • S. Allen, M. Dashwood, K. Morrison, M. Yacoub Differential leukotriene constrictor responses in human atherosclerotic coronary arteries Circulation, 97 (1988), pp. 2406-2413, 10.1161/01.CIR.97.24.2406 Google Scholar
  • R. Spanbroek, R. Gräbner, K. Lötzer, M. Hildner, A. Urbach, K. Rühling, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial Wall during human atherogenesis Proc Narl Acad Sci USA, 100 (2003), pp. 1238-1243, 10.1073/pnas.242716099 View Record in ScopusGoogle Scholar
  • G. Folco, G. Rossoni, C. Buccellati, F. Berti, J. Maclouf, A. Sala Leukotrienes in cardiovascular diseases Am J Respir Crit Care Med (2000), pp. S112-S116, 10.1164/ajrccm.161.supplement_1.ltta-22 CrossRefView Record in ScopusGoogle Scholar
  • Y. Kaetsu, Y. Yamamoto, S. Sugihara, T. Matsuura, G. Igawa, K. Matsubara, et al. Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro Cardiovasc Res, 76 (2007), pp. 160-166, 10.1016/j.cardiores.2007.05.018 CrossRefView Record in ScopusGoogle Scholar
  • S. Ge, G. Zhou, S. Cheng, D. Liu, J. Xu, G. Xu, et al. Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model Atherosclerosis (2009), pp. 74-79, 10.1016/j.atherosclerosis.2008.11.012 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • V. Capra, C. Carnini, M.R. Accomazzo, A. Di Gennaro, M. Fiumicelli, E. Borroni, et al. Autocrine activity of cisteinyl leukotrienes in human vascular endothelial cells: signalling through the CysLT2 receptor Prostaglandins Other Lipid Mediat, 120 (2015), pp. 115-125, 10.1016/j.prostaglandins.2015.03.007 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • H. Bisgaard Leukotriene modifiers in paediatric asthma management Pediatrics, 107 (2001), pp. 381-390, 10.1542/peds.107.2.381 View Record in ScopusGoogle Scholar
  • M. Bäck, S.E. Dahlén, J.M. Drazen, J.F. Evans, C.N. Serhan, T. Shimizu, et al. International union of basic and clinical pharmacology. LXXXIV: Leukotriene receptor nomenclature, distribution, and pathophysiological functions Pharmacol Rev, 63 (2011), pp. 539-584, 10.1124/pr.110.004184 CrossRefView Record in ScopusGoogle Scholar
  • V. Capra, M. Bäck, S.S. Barbieri, M. Camera, E. Tremoli, G.E. Rovati Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke Med Res Rev, 33 (2013), pp. 364-438, 10.1002/med.21251 CrossRefView Record in ScopusGoogle Scholar
  • C.F. Mueller, K. Wassmann, J.D. Widder, S. Wassmann, C.H. Chen, B. Keuler, et al. Multidrug resistance protein-1 affects oxidative stress endothelial dysfunction and atherogenesis via leukotriene C4 export Circulation, 117 (2008), pp. 2912-2918, 10.1161/circulationha.107.747667 View Record in ScopusGoogle Scholar
  • N. Bıber, H.Z. Toklu, S. Solakoglu, M. Gultomruk, T. Hakan, Z. Berkman, et al. Cysteinyl-leukotriene receptor antagonist montelukast decreases blood–brain barrier permeability but does not prevent oedema formation in traumatic brain injury Brain Injury, 23 (2009), pp. 577-584, 10.1080/02699050902926317 CrossRefView Record in ScopusGoogle Scholar
  • G.L. Yu, E.Q. Wei, M.L. Wang, W.P. Zhang, S.H. Zhang, J.Q. Weng, et al. Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice Brain Res, 1053 (2005), pp. 116-125, 10.1016/j.brainres.2005.06.046 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • G.L. Yu, E.Q. Wei, S.H. Zhang, H.M. Xu, L.S. Chu, W.P. Zhang, et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose-and time-dependently protects against focal cerebral ischemia in mice Pharmacology, 73 (2005), pp. 31-40, 10.1159/000081072 CrossRefView Record in ScopusGoogle Scholar
  • X.D. Qian, E.Q. Wei, L. Zhang, W.W. Sheng, M.L. Wang, W.P. Zhang, et al. Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, protects mice against brain cold injury Eur J Pharmacol, 549 (2006), pp. 35-40, 10.1016/j.ejphar.2006.07.056 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Bäck Inhibitor of the 5 lipoxygenase pathway in atherosclerosis Curr Pharm Des, 15 (2009), pp. 3116-3132, 10.2174/138161209789058020 CrossRefView Record in ScopusGoogle Scholar
  • G. Riccioni, V. Capra, N. D’Orazio, T. Bucciarelli, L.A. Bazzano Leukotriene modifiers in the treatment of cardiovascular diseases J Leukocyte Biol, 84 (2008), pp. 1374-1378, 10.1189/jlb.0808476 CrossRefView Record in ScopusGoogle Scholar
Fuente de los datos: Dialnet